<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>MAXIDEX- dexamethasone sodium phosphateÂ ointmentÂ </strong><br>Alcon<br></p></div>
<h1></h1>
<div class="Contents">
<div class="Section">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="description"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First"><span class="Bold">MAXIDEXÂ®</span>(Dexamethasone Sodium Phosphate) is an adrenocortical steroid prepared as a sterile ophthalmic ointment.  The active ingredient is represented by the chemical structure:</p>
<p><img alt="Image from Drug Label Content" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=863fb43c-dd33-485b-9385-744db7a98b83&amp;name=Maxidex-01.jpg"></p>
<p>Established name:</p>
<p>Dexamethasone Sodium Phosphate</p>
<p><span class="Bold">Chemical name:</span></p>
<p><span class="Bold">Pregn-4-ene-3,20-dione,9-fluoro-11,17-dihydroxy-16-methyl-21-(phosphonoxy)-, disodium salt, (11Î²,16Î±)-.</span></p>
<p>Each gram contains:  <span class="Bold">Active:</span> Dexamethasone Sodium Phosphate equivalent to  Dexamethasone Phosphate 0.5 mg (0.05%)  <span class="Bold">Inactive:</span>  Mineral Oil.</p>
<p>White Petrolatum.Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â DM-00</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="clinical-pharmacology"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Dexamethasone sodium phosphate suppresses the inflammatory response to a variety of agents and it probably delays or slows healing.  No generally accepted explanation of these steroid properties has been advanced.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="indciations-and-usage"></a><a name="section-4"></a><p></p>
<h1>INDCIATIONS AND USAGE</h1>
<p class="First">Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe.  These include <span class="product-label-link" type="condition" conceptid="374959" conceptname="Contact blepharoconjunctivitis">allergic conjunctivitis</span>, <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> <span class="product-label-link" type="condition" conceptid="136773" conceptname="Rosacea">rosacea</span>, superficial punctate keratits, <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">herpes zoster</span> <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">keratitis</span>, <span class="product-label-link" type="condition" conceptid="4274964" conceptname="Iritis">iritis</span>, cyclitis, selected infective conjunctivities when the inherent hazard of steroid use is accepted to obtain an advisable diminution in <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> and <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>; corneal injury from chemical or <span class="product-label-link" type="condition" conceptid="4022094" conceptname="Thermal burn">thermal burns</span>, or penetration of foreign bodies.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="contrainindications"></a><a name="section-5"></a><p></p>
<h1>CONTRAININDICATIONS</h1>
<p class="First">Contraindicated in epithelial <span class="product-label-link" type="condition" conceptid="373404" conceptname="Ophthalmic herpes simplex">herpes simplex keratitis</span> (<span class="product-label-link" type="condition" conceptid="373404" conceptname="Ophthalmic herpes simplex">dendritic keratitis</span>); fungal diseases of ocular structures; acute infectious stages of <span class="product-label-link" type="condition" conceptid="140633" conceptname="Vaccinia">vaccinia</span>, <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">varicella</span> and many other viral disease of the cornea and conjunctiva; <span class="product-label-link" type="condition" conceptid="4009326" conceptname="Mycobacterial infection">mycobacterial infection</span> of the eye and in those persons who have shown <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any component of this preparation.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="warnings"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">Prolonged use may result in <span class="product-label-link" type="condition" conceptid="381290" conceptname="Ocular hypertension">ocular hypertension</span> and/or <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, with damage to the optic nerve, defects in visual acuity and fields of vision, and <span class="product-label-link" type="condition" conceptid="375256" conceptname="Anterior subcapsular polar senile cataract">posterior subcapsular cataract</span> formation.  Prolonged use may suppress the host response an thus increase the hazard of secondary ocular <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.  In those diseases causing thinning of the cornea or sclera, perforations have been known to occur with the use of topical corticosteroids.  In acute purulent conditions of the eye, corticosteroids may mask <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> or enhance existing <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.  If these products are used for 10 days or longer, intraocular pressure should be routinely monitored even though it may be difficult in children and uncooperative patients.  Employment of corticosteroid medication in the treatment of herpes simplex other than epithelial <span class="product-label-link" type="condition" conceptid="373404" conceptname="Ophthalmic herpes simplex">herpes simplex keratitis</span>, in which it is contraindicated, requires great caution; periodic slit-lamp microscopy is essential.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="precautions"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="precautions-general"></a><a name="section-7.1"></a><p></p>
<h2>General</h2>
<p class="First">The possibility of persistent <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infections</span> of the cornea should be considered after prolonged corticosteroid dosing.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="general-information-for-patients"></a><a name="section-7.2"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">Do not touch tube tip to any surface, as this may contaminate the contents.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="information-for-patients-carcinogenesis-mutagenesis-impairment-of-fertility"></a><a name="section-7.3"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Long-term animal studies have not been performed to evaluate the carcinogenic potential or the effect on fertility of MAXIDEXÂ® Ointment.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="carcinogenesis-mutagenesis-impairment-of-fertility-pregnancy"></a><a name="section-7.4"></a><p></p>
<h2>Pregnancy</h2>
<p class="First">Pregnancy Category C.  Dexamethasone has been shown to be teratogenic in mice and rabbits following topical ophthalmic application in multiples of the therapeutic dose.</p>
<p>In the mouse, corticosteroids produce fetal resorptions and a specific abnormality, <span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">cleft palate</span>.  In the rabbit, corticosteroids have produced fetal resorptions and multiple abnormalities involving the head, ears, limbs, palate, etc.</p>
<p>There are no adequate or well-controlled studies in pregnant women.  MAXIDEX Ointment should be used during pregnancy only if the potential benefit to the mother justifies the potential risk to the embryo or fetus.  Infants born of mothers who have received substantial doses of corticosteroids during pregnancy should be observed carefully for signs of <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">hypoadrenalism</span>.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="pregnancy-nursing-mothers"></a><a name="section-7.5"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">Topically applied steroids are absorbed systemically.  Therefore, because of the potential for serious adverse reactions in nursing infants from dexamethasone sodium phosphate, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="nursing-mothers-pediatric-use"></a><a name="section-7.6"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Safety and effectiveness in children have not been established.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="adverse-reactions"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">The following adverse reactions have been reported:  <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> with optic <span class="product-label-link" type="condition" conceptid="381732" conceptname="Nerve injury">nerve damage</span>, visual acuity and field defects, <span class="product-label-link" type="condition" conceptid="375256" conceptname="Anterior subcapsular polar senile cataract">posterior subcapsular cataract</span> formation, secondary ocular <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> from pathogens including herpes simplex, and perforation of the globe.  Rarely, filtering blebs have been reported when topical steroids have been used following <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span> surgery.  Rarely, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">stinging</span> or burning may occur.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="dosage-and-adminstration"></a><a name="section-9"></a><p></p>
<h1>DOSAGE AND ADMINSTRATION</h1>
<p class="First">The duration of treatment will vary with the type of lesion and may extend from a few days to several weeks, according to therapeutic response.  Relapses, more common in chronic active lesions than in self-limited conditions, usually respond to treatment.  Apply a one-half to one inch ribbon of ointment into the conjunctival sac(s) up to four times daily.  When a favorable response is observed, dosage may be reduced gradually to once a day application for several days.  MAXIDEX Ointment may be used in conjunction with MAXIDEX suspension.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="how-to-apply-maxidex-ointment"></a><a name="section-10"></a><p></p>
<h1>HOW TO APPLY MAXIDEX OINTMENT</h1>
<ol>
<li>Tilt your head back.</li>
<li>Place a finger on your cheek just under your eye and gently pull down until a â€œVâ€? pocket is formed between your eyeball and your lower lid.</li>
<li>Place a small amount (about Â½ inch) of MAXIDEX in the â€œVâ€? pocket.  Do not let the tip of the tube touch your eye.</li>
<li>Look downward before closing your eye.</li>
</ol>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="how-supplied"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">In 3.5g ophthalmic tubes.</p>
<p>NDC 0065-0616-35</p>
<div class="Section" data-sectionCode="44425-7">
<a name="how-supplied-storage"></a><a name="section-11.1"></a><p></p>
<h2>STORAGE</h2>
<p class="First">Store at 8Â° - 27Â°C (46Â° to 80Â°F).</p>
<p><span class="Bold">CAUTION:</span> Federal (USA) law prohibits dispensing without prescription.</p>
<p><span class="Bold">ALCONÂ®</span></p>
<p><span class="Bold">Ophthalmic</span></p>
<p><span class="Bold">Alcon Laboratories, Inc.</span></p>
<p><span class="Bold">Fort Worth,  TexasÂ    76134</span></p>
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>MAXIDEXÂ 		
					</strong><br><span class="contentTableReg">dexamethasone sodium phosphate ointment</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0065-0616</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">OPHTHALMIC</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>dexamethasone sodium phosphate</strong> (dexamethasone phosphate) </td>
<td class="formItem"></td>
<td class="formItem">0.5Â mg Â inÂ 1Â g</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>mineral oil</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>white petrolatum</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0065-0616-35</td>
<td class="formItem">3.5 g in 1 TUBE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Alcon</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 12/2006<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>6E79C53E-5BB9-31F8-DE1A-81B0BA2FD270</div>
<div>Set id: 863fb43c-dd33-485b-9385-744db7a98b83</div>
<div>Version: 1</div>
<div>Effective Time: 20061226</div>
</div>
</div>Â <div class="DistributorName">Alcon</div></p>
</body></html>
